Investor profile for Ayuh Ventures: stage-based planning range, investment stages, sector focus, portfolio companies, sources, and verification status. Part of the Venture Capital Tracker directory.

VC fund profile · evidence-aware directory data

Ayuh Ventures stages, portfolio and investment profile

Ayuh Ventures invests in healthcare technology, with disclosed exposure to neuroscience, therapeutics, medical devices and drug-discovery tools. Its portfolio includes companies developing treatments and technologies for mental health, women's health and other underserved clinical needs.

Keep track of Ayuh Ventures

Save this profile to your VCT watchlist for a quick return.

View watchlist

Stage-based planning range

$250K–$3M

This is a planning range inferred from stage coverage, not a firm-disclosed check size.

Methodology: Stage bucket inferred from the rounds a fund leads or invests in.

No firm-specific check-size disclosure is recorded.

Source link not recorded Confidence: 25% Verified: November 15, 2026 View methodology

Investment stages

Leads: Not recorded

Participates: Pre-Seed, Seed, Series B

Sector focus

healthtech · biotech-life-sciences

Geography

New York City, New York, United States

Founded 2021

Fund size / AUM

Not recorded

A separate fund-size evidence record is not yet available.

Portfolio in our directory

3

Linked startup profiles

Recent tracked investment

Not recorded

No dated round explicitly links this fund.

VCT investor research

Inside Ayuh Ventures's investment strategy

Independent, source-backed analysis of who the firm backs, deal evidence and whether it fits your stage. Research checked 15 Nov 2026.

What does Ayuh Ventures invest in?

Ayuh Ventures is a New York healthcare investor with a portfolio spanning neuroscience, therapeutics, medical devices and drug-discovery tools. Its official website highlights Samphire Neuroscience, Gilgamesh Pharmaceuticals and Beckley Psytech.

These are different routes to improving health: a wearable device, a drug-development platform and a clinical-stage therapeutic business. The common thread is healthcare technology, rather than a single treatment format.

Which founders should consider Ayuh?

Founders developing neuroscience, mental-health, medical-device or therapeutic technologies have the clearest connection to its disclosed portfolio. Historical investments also include women's health, sexual health and drug-discovery platforms.

A useful introduction should make the scientific claim, validation achieved, next development milestone and route to customers or patients easy to understand. Clinical evidence, regulatory planning, intellectual property and financing needs matter differently for a device, a discovery platform and a drug candidate. This is preparation guidance based on the portfolio, not a firm-issued application rubric.

Investment stages and check size

Ayuh's historical reporting includes pre-seed, seed and Series B participation, with investments through both a fund and SPVs. A later-stage investment does not establish that the firm currently has a general later-stage mandate.

A standard current check range is not independently established here. Founders should confirm the individual investment size, lead or participant role, follow-on capacity and investing vehicle directly with the team.

Selected portfolio companies

CompanyBusinessContext
Samphire NeuroscienceWearable neurotechnology for women's healthAyuh is named in its 2024 pre-seed and 2025 seed financing coverage.
Gilgamesh PharmaceuticalsNeuropsychiatric drug developmentAbbVie completed the acquisition of its bretisilocin asset in October 2025; this is not evidence that every Gilgamesh program was acquired.
Beckley PsytechClinical-stage mental-health therapeuticsAtai completed the acquisition of the remaining Beckley shares in November 2025.

The transaction context matters: a historical portfolio company may subsequently sell an asset or become part of another business. Neither outcome, by itself, discloses Ayuh's realized proceeds or fund returns.

Documented funding-round participation

CompanyFinancingPublic round sizeEvidence
Samphire NeurosciencePre-seed; February 2024$2.3M total roundFIRSTPICK's published coverage names Ayuh among investors.
Samphire NeuroscienceSeed; announced June 3, 2025$5M total roundFinancing announcement names Ayuh among returning investors.

The 2025 round was co-led by Fortify Ventures and Inventure. Ayuh's individual contribution is undisclosed. Public sources use different announcement dates; VCT uses the dated announcements attached to the records, not an assumed legal closing date.

Publicly identified portfolio

The table combines the firm's website, its indexed AngelList portfolio and Kunal Sethi's historical 2022 longevity fund report. The report's original page is intermittently inaccessible; its indexed extracts provide historical context, not a current ownership register.

CompanyInvestment record
Beckley PsytechManager reports a 2021 Series B investment; also named on Ayuh's website.
Clerkenwell HealthManager reports a March 2022 Pre-Seed+ investment.
Gilgamesh PharmaceuticalsManager reports Series B participation in May 2022; also on Ayuh's website.
Kadence Bio, formerly Kanna HealthManager reports June 2022 Pre-Seed+ participation under the former name.
Samphire NeuroscienceManager reports April and August 2022 investments; later rounds documented above.
Lief TherapeuticsManager reports a 2021 SPV investment and a Fund I Seed+ follow-on.
Pepper BioManager reports a June 2022 seed investment.
Psy TherapeuticsManager reports April 2022 Seed+ participation.
Mindstate Design LabsNamed in Ayuh's indexed AngelList portfolio.
Reset PharmaceuticalsListed by investment databases, including aVenture; precise entry-round attribution needs primary confirmation.

AngelList's indexed portfolio corroborates several of these names. Kanna Health rebranded to Kadence Bio; they should not be counted as two investments.

Team and relationship with Prithvi Ventures

Kunal Sethi is General Partner, while Murali Sethumadhavan is Operating Partner. Their involvement is supported by Prithvi's official team biographies and Ayuh's company profile.

They also work with Prithvi Ventures, which concentrates on energy and industrial technology. The shared team is useful context, but each investment should be attributed to the firm or vehicle identified in its source.

How to explore further

Visit Ayuh's official website for its current positioning. Compare it with other investors in the New York hub and NYC early-stage directory.

For current corporate status, the strongest sources are AbbVie's completed bretisilocin transaction and Atai's Beckley acquisition filing. They establish what changed at the portfolio companies, not a return multiple for Ayuh.

Sources and verification

Dated company disclosures take priority over third-party databases. These sources support the analysis above.

Rounds they lead

Rounds they invest

Pre-Seed Seed Series B

Last verified: 2026-11-15. Check-size evidence is labeled by basis so planning estimates are not presented as firm disclosures.

FAQs about Ayuh Ventures

Stage fit, check size, thesis, and how founders typically approach this firm — based on public sources and our directory.

Healthcare, including neuroscience, mental-health therapeutics, medical devices and drug-discovery platforms. Its historical portfolio also includes women's and sexual health technologies.
New York City, according to its company profile.
Kunal Sethi is General Partner and Murali Sethumadhavan is Operating Partner. Both also work with Prithvi Ventures.
A current standard range has not been independently established. Founders should confirm investment size and vehicle directly with the firm.
The $5 million figure is Samphire Neuroscience's entire 2025 seed round. Ayuh was named among returning participants; its individual contribution was not disclosed.

By Venture Capital Tracker

Last updated:

Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.